This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Visual Function Changes After Intraocular Pressure Reduction

This study has been completed.
Information provided by:
University of Sao Paulo Identifier:
First received: February 12, 2007
Last updated: February 16, 2007
Last verified: February 2007
During the glaucomatous disease process, subpopulations of cells may be dead, damaged or healthy. Visual function changes could be observed due to a recovering of the suffering ganglion cells after the intraocular pressure reduction. This study aims at evaluating the correlation between intraocular pressure reduction and visual function changes in glaucoma patients after using antiglaucoma medications.

Condition Intervention
Glaucoma Drug: timolol maleate 0,5% Drug: brimonidine tartrate 0,2% Drug: travoprost 0,004%

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Visual Function Changes After Intraocular Pressure Reduction Using Antiglaucoma Medications: A Randomized Clinical Trial

Resource links provided by NLM:

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:
  • intraocular pressure
  • contrast sensitivity
  • visual quality perception

Secondary Outcome Measures:
  • Mean deviation of the visual field (MD)
  • Pattern Standard Deviation of the visual field (PSD)
  • visual acuity

Estimated Enrollment: 54
Study Start Date: September 2005
Estimated Study Completion Date: April 2006
Detailed Description:

Primary open angle glaucoma patients without use of antiglaucoma medications will be enrolled in this study. After inclusion, the patients will randomly receive one of three antiglaucoma medications (timolol maleate 0,5%, brimonidine tartrate 0,2% or travoprost 0,004%) in one randomly selected eye.

The patients will be evaluated with Goldmann applanation tonometry, visual acuity test, contrast sensitivity test, visual quality perception test (visual analogue scale) and standard automated perimetry before and after 4 weeks of glaucoma treatment onset.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary open angle glaucoma
  • Intraocular pressure greater than 21 mmHg

Exclusion Criteria:

  • Best corrected visual acuity (BCVA) worse than 20/80
  • Significant media opacity
  • History of steroid use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00435058

Sponsors and Collaborators
University of Sao Paulo
Principal Investigator: Tiago Prata, MD Federal University of Sao Paulo
Principal Investigator: Luiz A Melo Jr, MD Federal University of Sao Paulo
  More Information Identifier: NCT00435058     History of Changes
Other Study ID Numbers: CEP 1021/05
Study First Received: February 12, 2007
Last Updated: February 16, 2007

Keywords provided by University of Sao Paulo:
intraocular pressure
contrast sensitivity
visual function

Additional relevant MeSH terms:
Brimonidine Tartrate
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists processed this record on September 21, 2017